HELIOS Kliniken

Revision of the "guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations - Rili-BAEK" (2024) Ahmad-Nejad P, Bauersfeld W, Baum H, Behre HM, Burkhardt R, Cassens U, Ceglarek U, et al. Journal article Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (2024) Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, et al. Journal article Independent Factors Influencing Changes in Baroreceptor Sensitivity after Carotid Endarterectomy (2024) Yagshyyev S, Haney B, Li Y, Papatheodorou N, Zetzmann K, Meyer A, Meyer S, et al. Journal article Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024) de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al. Journal article Analysis of the German Compassionate Use Program on spesolimab in patients with generalized pustular psoriasis: evidence outside of clinical trials (2024) Krefting F, Welzel J, Thamm J, Thölken K, Wohlrab J, Müller VL, Kreuter A, et al. Journal article ABC7-Konsens zur Systemtherapie des fortgeschrittenen Mammakarzinoms (2024) Lüftner D, Ditsch N, Fasching P, Busch S, Ettl J, Haidinger R, Jackisch C, et al. Journal article Fetal Alcohol Spectrum Disorders in Adults: Consensus on Diagnosis and Position on Care and Research in Germany Fetale Alkoholspektrumstörungen bei Erwachsenen Konsens zur Diagnostik und Position zu Versorgung und Forschung in Deutschland (2024) Schecke H, Wagner J, Richter-Schmidinger T, Bolbecher G, Michalowski G, Landgraf MN, Feldmann R, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials (2024) Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, et al. Journal article Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article